相关实验视频

Updated: May 6, 2026

Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding

Assessment of Immunologically Relevant Dynamic Tertiary Structural Features of the HIV-1 V3 Loop Crown R2 Sequence by ab initio Folding

Published on: September 15, 2010

与达鲁纳维尔结合的HIV-1蛋白酶亚型C的结构影响:分子动力学研究

Sankaran Venkatachalam¹, Sowmya Ramaswamy Krishnan¹, Ramesh Pandian²

¹Department of Biotechnology, Bhupat and Jyoti Mehta School of Biosciences, Indian Institute of Technology Madras, Chennai, India.

|March 3, 2025

概括

艾滋病毒蛋白酶突变,如C亚型中的L38HL,可以通过改变酶结构和减少达鲁纳维尔结合,导致药物耐药性. 这会影响抗逆转录病毒疗法的有效性.

科学领域:

病毒学病毒学
结构生物学结构生物学
计算化学计算化学

背景情况:

人类免疫缺陷病毒 (HIV) 构成了全球卫生挑战,其遗传变异性阻碍了有效的治疗.
抗逆转录病毒疗法因耐药性HIV病毒株而面临障碍.
艾滋病毒蛋白酶对于病毒复制和成熟至关重要.

研究的目的:

研究Darunavir (DRV) 与野生型 (WT) 和HIV-1蛋白酶亚型C的L38HL变体的结合动态.
了解HIV蛋白酶变体中耐药性的结构和能量基础.

主要方法:

分子动力学模拟的模拟.
结构和动态交叉相关性分析分析.
有约束力的能源计算.

主要成果:

在HIV-1蛋白酶亚型C中的L38HL双插入改变了Φ和 Ψ角度,增加了波动和溶剂可访问的表面积.
结构变化影响紧性和疏水性核心,影响DRV结合.
对于L38HL-DRV复合物,观察到减少的键相互作用和结合能,表明药物耐药性.

结论:

在HIV-1蛋白酶亚型C中的L38HL突变显著影响了酶结构和动态.
这些变化导致与达鲁纳维尔的结合亲和力降低,导致药物耐药性.
研究结果提供了对HIV耐药性机制的见解,并为未来的治疗策略提供了信息.

关键词:

艾滋病艾滋病艾滋病是什么?这是一个DRV DRV.艾滋病病毒艾滋病病毒艾滋病病毒模拟MDMD的模拟达鲁纳病毒 (darunavir) 是一种病毒.蛋白质酶蛋白质酶是一种蛋白质.C亚型的C亚型是C亚型的

更多相关视频

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Nucleocapsid Annealing-Mediated Electrophoresis NAME Assay Allows the Rapid Identification of HIV-1 Nucleocapsid Inhibitors

Published on: January 19, 2015

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

相关概念视频

Protein-Drug Binding: Mechanism and Kinetics

Protein-Drug Binding: Mechanism and Kinetics

Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...